SIGA Technologies Inc (SIGA) 2023 Q4 法說會逐字稿

Welcome to the SIGA business update call.

Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or changed circumstances after this call.

For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission, including without limitation, the company's annual report on Form 10-K for the year ended December 31, 2023, and its subsequent reports on Form 10-Q and Form 8-K.

I will now hand the call over to Diem Nguyen, CEO of SIGA. Please go ahead.

Good afternoon, everyone, and thank you for joining today's call and review of our business results for the fourth quarter and full year of 2023. I am joined by Dan Luckshire, our Chief Financial Officer, and we're pleased to have this opportunity to provide an update to our shareholders. After the update, we'll be happy to answer any of your questions.

I'd like to begin by recognizing the work and contributions of Phil Gomez. He served as SIGA's CEO for seven years. Phil was instrumental in transforming our company into a more commercial organization, with sales in over 25 countries and securing key regulatory approvals for our TPOXX franchise. On behalf of our team, I want to thank Phil for his many contributions to making SIGA the strong company it is today.

On a personal note, I'm excited to join SIGA and take on the role of CEO. Having spent nearly three decades focused on addressing unmet needs in healthcare, I look forward to building on SIGA success and driving greater growth for the benefit of our patients, customers, and shareholders. I have a deep-seated passion for scientific advancement and innovation, as well as an extensive experience leading successful multibillion-dollar commercial organization. I'm extremely excited to leverage that experience to help fulfill SIGA's potential and have our essential therapies available worldwide.

Although this is only my sixth week with the company, I'm pleased to share my belief in SIGA's bright future. This belief has been grounded for the following. First, SIGA has strong business fundamentals. It is a highly profitable company with a management team that has deep expertise in commercial activities, antiviral R&D, and government relations.

And the company has built and maintains a fully integrated US-based operational supply chain. This is a distinguishing asset for our customers.

Second, TPOXX is a foundational product franchise that has a track record of securing multi-year government contracts, which have totaled over $1 billion in the past 10 years. Again, this is a point of distinction and speaks to the significant value of two parts.

Third, SIGA has achieved best-in-class financial performance. Our average annual TPOXX operating income over the past four years has been $75 million. These results have been achieved while maintaining a strong balance sheet.

Fourth, SIGA has attractive growth opportunities. Let me just mention a few. In the near term, SIGA has the potential to expand the indications of TPOXX, includes post-exposure prophylaxis, which we like to call PEP, and mpox. I'll provide an update on these programs a little later in these remarks.

Also in the near term, SIGA has the opportunity to expand geographically and work with governments across the world to fully embrace stockpiling and preparedness for full range of orthopoxvirus spread. We want to ensure governments have a modernized view of the risks and the tools for protection against orthopoxviruses.

And thinking more broadly, SIGA has strong antiviral and government procurement capabilities. We believe these capabilities are best in class that we can leverage to move into complementary therapeutic areas with similar points of patient care. Importantly, all of this has reinforced TPOXX leadership among infectious disease countermeasures.

SIGA's expertise, and experience in commercial execution, R&D, innovation, and government contracting enables us to support the highest level of public and individual safety. As a result of these four critical factors, I believe SIGA is well positioned for further innovation, strong business performance, and attractive value creation for our shareholders.

Now turning to our financial results. I am very pleased to report that we finished year strong. Full-year 2023's product revenues of $131 billion are the highest amount achieved over the past five years. This reflects a 51% increase over 2022. Approximately $116 million of the full-year product revenues were achieved in the fourth quarter coming from a diversity of sources, including the U.S. Strategic National Stockpile, or the SNS; the U.S. Department of Defense; and five international governments.

Pre-tax operating income was approximately $84 million in 2023, a 96% increase over 2022. This is a testament to the strength of the SIGA team, the value of our franchise, and the real brilliance of our company. Dan will provide more details on these results shortly.

Additionally, in 2023, we spent $43 million on capital management through a combination of special cash dividends and share buybacks. And I'm pleased to announce that our Board of Directors has declared a special dividend of $0.60 per share to pay paid in April. This represents a 33% increase over the special dividend we paid in June of 2023. This demonstrates the financial strength of our company and the confidence the Board and the management team have in our future.

Our proven track record, coupled with the potential of a new long-term contract with the SNS provides both a compelling and attractive backdrop for our company in both the short and longer term. Looking forward, we plan to continue to invest to grow our business while maintaining a balanced and disciplined capital allocation approach, with the goal of delivering strong long-term revenues and earnings growth, and creating value for our shareholders.

And now, I would like to talk about PEP and mpox program. With regard to PEP, I will start by recapping what was reported on the last investor call. Based on the studies and trials that have been conducted, we believe TPOXX benefits patients are in a prophylactic situation. The FDA has not asked for any additional studies prove the efficacy of TPOXX for pets, but has asked for extended safety data in humans for treatment for 28 days.

We have completed this requirement and the data is consistent with prior safety studies. It is important to emphasize that clinical trial results do not show any drug-related serious adverse events, consistent with the past existing strong safety profile. In addition to the safety trial, we have completed a journey of TPOXX immunogenicity trials solely to evaluate if TPOXX has an impact on the vaccine immune response, because in the event of an outbreak, TPOXX treatment would likely to be used in combination with smallpox vaccine.

In the preliminary analysis of the data from the immunogenicity trial, consistent with what we expected, the results did not show a meaningful difference between the immunogenicity of those who received the Jynneos vaccines while on placebo, compared to those that receive the Jynneos vaccines while on TPOXX. However, as mentioned previously, the results indicated that the number of volunteers who had measurable immune response to the Jynneos vaccine in both the placebo and TPOXX group was lower than expected.

Given this results that data deemed difficult process for the non-inferior statistical determination, which was necessary for the primary endpoint as originally planned in the study. On the last investor call, we also reported that a subset of the Jynneos and TPOXX samples from the immunogenicity trial were sent to our colleagues at the CDC who performed their validated print analysis on them. These samples showed the expected immune responses. As such, we are now working on getting the entire seven samples reanalyzed, given the challenges associated with a prior analysis conducted by our CRO vendor.

We believe these preliminary CDC analyses provide a potential path forward, despite the unexpected nature of the prior results. As such, in parallel, we are working towards a supplemental NDA submission within the next 12 months. We are grateful to our colleagues at the CDC for this collaboration and efficient path forward. We believe this is the best course of action in terms of getting timely data from the immunogenicity trials, and the FDA agreed as they have been briefed on our plan and had not voiced any objections.

As a final comment on the PEP program, I want to emphasize that the immunogenicity analysis are not about the efficacy or safety of TPOXX, nor are they about TPOXX impact of those individuals who are showing an immune response, rather, the relevance of immunogenicity study is that in the case of an orthopoxvirus epidemic, be it mpox or smallpox, use of TPOXX with the vaccine for PEP will be important to reduce the morbidity and mortality of the population without sacrificing patient safety.

Now, I would like to shift gears and provide a quick update on the current mpox trials involving TPOXX, which include four randomized controlled trials, as well as multiple observational studies. These studies continue to enroll patients and collect data to provide some specific data points.

In Africa, as of February, the NIAID PALM trial being conducted in the DRC has enrolled approximately 425 patients, a large increase from the 314 patients noted in our last call. In the NIAID's top trial as of February, there were 267 patients, which is also a substantial increase from the 157 patients noted in our last call. These increases in patient numbers demonstrates that the case counts continue to accumulate, especially in Africa.

Importantly, they also provided some glimpse, some would say a warning, into the overall global health risks posed by orthopoxviruses. As such, we are working closely with the NIH and other health agencies on randomized clinical trials to demonstrate whether TPOXX is safe and effective for treating mpox in Africa, the US, and other parts of the world to achieve the best possible outcome for mpox patients from a public health perspective.

I would like to remind, however, TPOXX is approved for smallpox, and mpox, cowpox, and a series complications in Europe and in the UK. At this point, I would like to turn the call over to Dan for the financial update.

Thanks, Diem. As noted earlier in the call, SIGA's strong performance is represented in 2023. Product sales for the 12 months ended December 31, 2023, were $131 million, which is the highest demand achieved over the past five years and reflects a 51% increase over 2022. $116 million of the full-year product sales were achieved in the fourth quarter.

Coming from the diversity of sources, including the U.S. Strategic National Stockpile, the U.S. Department of Defense, and five international governments, fourth-quarter product sales include net product sales of $98 million for the delivery of oral TPOXX, $6 million oral TPOXX sales to the US Department of Defense, and $12 million of international sales of oral TPOXX, most of which relates to orders under the HERA contract announced in October 2023.

I would like to add that the process of product deliveries under existing orders, which started in the fourth quarter of 2023 continued in the first two months of 2024, with approximately $15 million of deleverage of quality products to the SNS, and approximately $7 million of international deliveries of oral TPOXX.

Pre-tax operating income, which excludes interest income and taxes was approximately $84 million for 2023. This represents an increase of 96% over the corresponding 2022 amounts are right to note that average pretax operating income for the past four years, a time period of 2020 to 2023 is $75 million. We believe this average and the 2023 financial results highlight the robust and in power of SIGA.

Continuing this strong performance, net income for 2023 was $68 million, an increase of approximately 100% from the corresponding amount in 2022. In turn, fully diluted income per share for 2023 was $0.95 versus $0.46 in 2022.

At December 31, 2023, the company maintained a strong balance sheet with a cash balance of approximately $150 million and no debt. In 2023, biggest spend is approximately $43 million in capital management, with a special cash dividend of approximately $32 million and share repurchases of approximately $11 million. Earlier today, the company declared a special cash dividend of $0.60 per share payable on April 11, for shareholders of record at the close of business on March 26.

This concludes the financial update. At this point, I'll turn the call back to Diem.

Thank you, Dan. Before I conclude our prepared remarks, I'd like to offer one more insight to my role as CEO. I am committed to creating shareholder value for our shareholders by doing what I believe is best in the long-term interest of our company, partners, and patients. I am bringing a fresh perspective with a sense of urgency through our strategic planning, operational processes, development efforts, and capital allocation just to name a few. You'll be hearing more from me in the coming months as our plans evolve, and we leverage the progress and momentum from 2023 into 2024.

So in summary, our company is in an exciting and important launch moments, as we strategically invest in our research and development programs, expand geographically by broadening our partnerships with governments around the world, leverage our antiviral experience and expertise to pursue attractive opportunities in other therapeutic areas with similar points of patient care, and continued initiatives that directly benefit our shareholders.

Now, I would like to open the call to Q&A.

(Operator Instructions) Soo Romanoff, Edison Group.

Great. Thank you for taking my questions and congratulations on the quarter. It's nice to see the healthy distributions. My first question was on oral TPOXX delivery. It looks like we will mark the last deliveries under the 2018 contract with BARDA for oral TPOXX. Have we had any other further discussions with the government -- the US government on possible extensions to the contract, or new long-term rolling SNS contract?

Thank you, Soo, for the question. We want to share that we have maintained a continued, as well as healthy dialogue, with the US government. At this time, we're targeting an RFP for the SNS from the administration of strategic preparedness and response this year. Specifically, we're not in a position to point or pinpoint the exact timing, but we do know that we're prepared to engage in any conversation and address any needs that they may have. Thank you.

My second question was really on HERA. I mean, that was a really big milestone for SIGA, and it was -- have we seen any incremental opportunities develop in the last few months? We saw that nice in a double-digit million of procurement deal that was already signed. What kind of other sales potentials can we assume looking ahead?

At this point, as you have all been aware, we have sold to more than 25 countries. There are multiple countries in Europe and beyond who have ordered in the past who are indicating interest in ordering more TPOXX, often a larger quantity than the prior order. These conversations tend to be productive, but yet iterative. So we will share once we're able to.

I will note that we've had $21 million in international sales in 2023. And we are looking to strengthen these sales in the years ahead.

Great. Thank you so much.

(Operator Instructions) George Hill, a private investor.

Hi. Yes. I'm not sure if you covered this earlier in the call, but do you -- does SIGA still have an option coming up for later this year, the final option exercise for TPOXX for the US government?

Yeah. So this is Dan. And you're correct and that existing contract does have a remaining option for $113 million for oral TPOXX, as well as an IV TPOXX option for $26 million.

I would note that (multiple speakers)

Okay. And that is --

I'm sorry, go ahead.

That's for the '24 fiscal year?

That's what we're targeting, is that those options we are targeting to get exercised this year.

Okay, thank you.

Lance Kimbrough, Ivy Creek Capital.

Congratulations on the great 2023 results. My question was related to on in the last quarter call. You had highlighted that there was some manufacturing bottlenecks that were kind of holding up deliveries. It looks like or sounds like you worked through those. It was also mentioned that the reorder cycle for 2024 would be approximately $128 million. Do you feel like manufacturing capacity now is such that you can meet that target if it's fulfilled?

Sure. This is Dan. I'll start off and Diem can jump in if she wants. And yeah, we did navigate the slow pace of the supply chain toward the end of the year. We are still working on getting that to a more normalized way, which I'm not going to say that it's back to where it was a couple of years ago, but we did manage to get deliveries within the fourth quarter for the most part.

Going forward, it will be a continuing focus. Timing is important in terms of when the order comes in, in terms of when deliveries are made. But provided that we get a timely order from the US government, then we will be working toward making at least a substantial portion of deliveries this year.

And Lance, I would just add that given my experiences running large or commercialized organizations, I recognize the importance of a strong manufacturing capability. So within the weeks that I joined, I started to take a deep dive on the manufacturing partnerships, how we can be more effective in communications, and you will see that we will be working towards successful delivery of products in the future.

Great. All right. Well, congratulations again on the great results.

Thank you, Lance.

Thank you. There are no further questions at this time. Please proceed.

So thank you, Jenny. I just want to pause and say thank you for everyone for their time today, and their continued interest in SIGA. As I mentioned in my remarks earlier, SIGA is in an exciting and important launch moment. We look forward to providing an update with our progress next quarter, and thank you to everyone. Have a great day.

Thank you. Ladies and gentlemen, the conference has now ended. Thank you all for joining. You may all disconnect.